THE EFFECTIVENESS OF LONG-TERM USE OF THIOTROPIUM IN COPD PATIENTS (TIOSPIR STUDY REGIONAL SUB-ANALYSIS)

Yu. M. Mostovoy, T. V. Konstantinovich, A. V. Demchuk Abstract

Within the frames of international multicenter study TIOSPIR the authors have evaluated the effect of thiotropium bromide (Spiriva®) on the course of chronic obstructive pulmonary disease (COPD) in 32 patents (29 males and 2 females, mean age (63,0 \pm 9,8) years). Mean treatment duration was (2,35 \pm 0,34) years.

The rate of COPD exacerbations/hospitalizations, influence on cardiovascular system, economical aspects and treatment compliance were analyzed.

It was established that long-term treatment with thiotropium was associated with less COPD exacerbations/hospitalizations and lower cost of exacerbation management.

Combination of thiotropium with inhaled corticosteroids and longacting beta-2 agonists led to better control of the disease in patients with severe course of COPD.

Key words: chronic obstructive pulmonary disease, thiotropium bromide, effectiveness of long-term use.

Ukr. Pulmonol. J. 2015; 2:56-59.

Yurii M. Mostovyi Vinnytsia national medical university named after M. I. Pyrogov MOH of Ukraine Chief of internal diseases propaedeutics chair Doctor of medicine, professor 28/59, 600-richia, Vinnytsia, 21021, Ukraine Tel.: 380432 44-62-30, mostvin@mail.ru